Quorum

Quorum Innovations is a clinical-stage biopharmaceutical company focused on the human microbiome and the science of quorum sensing, or bacterial communication. The company develops microbiome-derived therapies that modulate these communication pathways to treat inflammatory, infectious, and metabolic diseases. Their lead candidate, QI-101, is a novel topical therapy currently in Phase 2 clinical trials for the treatment of atopic dermatitis. Beyond its therapeutic pipeline, Quorum Innovations leverages its platform to develop specialty ingredients and consumer healthcare products designed to restore and maintain a healthy microbiome balance.